← Leaderboards
Vladimir R Muzykantov
University Of Pennsylvania
$31,969,177
Attributed
$38,261,438
Total exposure
21
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,261,438 · 21
By mechanism
R01$36,371,859 · 18
P01$1,721,815 · 1
P50$155,764 · 1
R13$12,000 · 1
Top collaborators
- Drew Weissman6 shared
- Jacob Brenner4 shared
- Douglas Brock Cines4 shared
- Wenchao Song4 shared
- G Scott Worthen3 shared
- Kenneth Ber Margulies2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Trevor M. Penning$29,812,455
- Ian Alexander Blair$30,276,296
- Jason A Burdick$12,143,168
- Wenchao Song$30,516,555
- Felix W Wehrli$41,563,685
Others in their field
Top investigators on “Drug Delivery Systems”
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Gerald Van Belle · University Of Washington$48,120,734
- David Heimbrook · Leidos Biomedical Research, Inc.$47,325,954
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$38,382,452
- Martin Friedlander · Scripps Research Institute$36,319,942
Research focus
Drug Delivery SystemsBloodBlood VesselsPharmaceutical PreparationsIn VivoLungDesignAnimalsEndotheliumMouse ModelInflammationEndothelial CellsTranslationsAntibodiesAcuteAnimal ModelMediatingAffinityAnti-Inflammatory AgentsAdverse EffectsCellsBaseSiteTissues
Grant awards (80)
Cardiac delivery of RNA to treat contractile disorder$796,655
R01 · FY2025 · HL
Controlling complement to unleash nanomedicine for acute critical illnesses$695,095
R01 · FY2025 · HL
Cardiac delivery of RNA to treat contractile disorder$793,828
R01 · FY2024 · HL
Vascular Targeting of Nanocarriers for RNA$767,434
R01 · FY2024 · HL · contact PI
Dual drug delivery to lung/blood interface in respiratory infections.$698,173
R01 · FY2024 · HL · contact PI
Controlling complement to unleash nanomedicine for acute critical illnesses$681,194
R01 · FY2024 · HL
BC-mediated delivery of thromboprophylaxis$653,281
R01 · FY2024 · HL · contact PI
Vascular Targeting of Nanocarriers for RNA$792,842
R01 · FY2023 · HL · contact PI
Dual drug delivery to lung/blood interface in respiratory infections.$721,126
R01 · FY2023 · HL · contact PI
Controlling complement to unleash nanomedicine for acute critical illnesses$695,095
R01 · FY2023 · HL
BC-mediated delivery of thromboprophylaxis$666,613
R01 · FY2023 · HL · contact PI
Vascular Targeting of Nanocarriers for RNA$801,819
R01 · FY2022 · HL · contact PI
Dual drug delivery to lung/blood interface in respiratory infections.$726,891
R01 · FY2022 · HL · contact PI
BC-mediated delivery of thromboprophylaxis$666,613
R01 · FY2022 · HL · contact PI
Controlling complement to unleash nanomedicine for acute critical illnesses$626,215
R01 · FY2022 · HL
Dual drug delivery to lung/blood interface in respiratory infections.$742,310
R01 · FY2021 · HL · contact PI
Vascular Targeting of Nanocarriers for RNA$726,234
R01 · FY2021 · HL · contact PI
Vascular delivery of nanocarriers by erythrocyres$702,164
R01 · FY2021 · HL · contact PI
BC-mediated delivery of thromboprophylaxis$659,978
R01 · FY2021 · HL · contact PI
Vascular delivery of nanocarriers by erythrocyres$705,544
R01 · FY2020 · HL · contact PI
Vascular delivery of nanocarriers by erythrocyres$709,769
R01 · FY2019 · HL · contact PI
Endothelial targeting of antioxidants$496,564
R01 · FY2019 · HL · contact PI
Vascular delivery of nanocarriers by erythrocyres$730,596
R01 · FY2018 · HL · contact PI
Targeted nanomedicine for ALI and I/R$569,442
R01 · FY2018 · HL · contact PI
Targeting novel biotherapeutics to endothelium$550,554
R01 · FY2018 · HL · contact PI
Endothelial targeting of antioxidants$511,951
R01 · FY2018 · HL · contact PI
Drug delivery by carrier erythrocytes$636,016
R01 · FY2017 · HL · contact PI
Targeted nanomedicine for ALI and I/R$569,442
R01 · FY2017 · HL · contact PI
Targeting novel biotherapeutics to endothelium$549,646
R01 · FY2017 · HL · contact PI
Endothelial targeting of antioxidants$322,000
R01 · FY2017 · HL · contact PI
Drug delivery by carrier erythrocytes$657,458
R01 · FY2016 · HL · contact PI
Targeted nanomedicine for ALI and I/R$569,442
R01 · FY2016 · HL · contact PI
Targeting novel biotherapeutics to endothelium$549,646
R01 · FY2016 · HL · contact PI
Prevention and management of perioperative pulmonary embolism$401,875
R01 · FY2016 · HL
Endothelial targeting of antioxidants$321,500
R01 · FY2016 · HL · contact PI
Drug delivery by carrier erythrocytes$647,597
R01 · FY2015 · HL · contact PI
Targeted nanomedicine for ALI and I/R$569,442
R01 · FY2015 · HL · contact PI
Targeting novel biotherapeutics to endothelium$549,646
R01 · FY2015 · HL · contact PI
Prevention and management of perioperative pulmonary embolism$395,846
R01 · FY2015 · HL
Drug delivery by carrier erythrocytes$605,758
R01 · FY2014 · HL · contact PI
Prevention and management of perioperative pulmonary embolism$393,838
R01 · FY2014 · HL
Drug delivery by carrier erythrocytes$23,300
R01 · FY2014 · HL · contact PI
Prevention and management of perioperative pulmonary embolism$396,865
R01 · FY2013 · HL
Targeted delivery of thrombomodulin in lung disease$371,102
R01 · FY2013 · HL · contact PI
Targeting Carriers with Controlled Geometry to Endothelium$389,813
R01 · FY2012 · HL · contact PI
Targeted delivery of thrombomodulin in lung disease$389,813
R01 · FY2012 · HL · contact PI
Delivery of Anti-thrombotic Drugs by Blood Cells$389,813
R01 · FY2012 · HL · contact PI
2012 Drug Carriers in Medicine and Biology Gordon Research Conference$12,000
R13 · FY2012 · EB · contact PI
Delivery of Anti-thrombotic Drugs by Blood Cells$393,750
R01 · FY2011 · HL · contact PI
Targeted delivery of thrombomodulin in lung disease$393,750
R01 · FY2011 · HL · contact PI
Targeting Carriers with Controlled Geometry to Endothelium$393,750
R01 · FY2011 · HL · contact PI
Delivery of Anti-thrombotic Drugs by Blood Cells$393,750
R01 · FY2010 · HL · contact PI
Targeted delivery of thrombomodulin in lung disease$393,750
R01 · FY2010 · HL · contact PI
Targeting Carriers with Controlled Geometry to Endothelium$393,750
R01 · FY2010 · HL · contact PI
Delivery of Anti-thrombotic Drugs by Blood Cells$393,750
R01 · FY2009 · HL · contact PI
Targeting Carriers with Controlled Geometry to Endothelium$393,750
R01 · FY2009 · HL · contact PI
Targeted delivery of thrombomodulin in lung disease$393,750
R01 · FY2009 · HL · contact PI
POLYMER NANOCARRIERS FOR DELIVERY OF ANTI-OXIDANTS TO ENDOTHELIUM$356,671
P01 · FY2009 · HL · contact PI
Delivery of Anti-thrombotic Drugs by Blood Cells$393,750
R01 · FY2008 · HL · contact PI
Targeting Carriers with Controlled Geometry to Endothelium$393,750
R01 · FY2008 · HL · contact PI
POLYMER NANOCARRIERS FOR DELIVERY OF ANTI-OXIDANTS TO ENDOTHELIUM$338,192
P01 · FY2008 · HL · contact PI
POLYMER NANOCARRIERS FOR DELIVERY OF ANTI-OXIDANTS TO ENDOTHELIUM$379,698
P01 · FY2007 · HL · contact PI
Augmentation of Antioxidant Defenses by Immunotargeting$375,716
R01 · FY2007 · HL · contact PI
Augmentation of Antioxidant Defenses by Immunotargeting$386,938
R01 · FY2006 · HL · contact PI
POLYMER NANOCARRIERS FOR DELIVERY OF ANTI-OXIDANTS TO ENDOTHELIUM$351,165
P01 · FY2006 · HL · contact PI
Augmentation of Antioxidant Defenses by Immunotargeting$396,250
R01 · FY2005 · HL
Targeting of Drugs to ICAM$356,625
R01 · FY2005 · HL
POLYMER NANOCARRIERS FOR DELIVERY OF ANTI-OXIDANTS TO ENDOTHELIUM$296,089
P01 · FY2005 · HL
Nanocarriers for delivery of antioxidants to endothelium$396,250
R01 · FY2004 · HL
Augmentation of Antioxidant Defenses by Immunotargeting$396,250
R01 · FY2004 · HL
Targeting of Drugs to ICAM$356,625
R01 · FY2004 · HL
THROMBOPROPHYLAXIS IN THE SURGICAL SETTING$277,375
R01 · FY2004 · HL
Targeting of Drugs to ICAM$342,467
R01 · FY2003 · HL
THROMBOPROPHYLAXIS IN THE SURGICAL SETTING$277,375
R01 · FY2003 · HL
Targeting of Drugs to ICAM$336,150
R01 · FY2002 · HL
THROMBOPROPHYLAXIS IN THE SURGICAL SETTING$277,375
R01 · FY2002 · HL
AUGMENTATION OF ANTIOXIDANT DEFENSES BY IMMUNOTARGETING$0
P50 · FY2002 · HL
THROMBOPROPHYLAXIS IN THE SURGICAL SETTING$277,375
R01 · FY2001 · HL
AUGMENTATION OF ANTIOXIDANT DEFENSES BY IMMUNOTARGETING$0
P50 · FY2001 · HL
AUGMENTATION OF ANTIOXIDANT DEFENSES BY IMMUNOTARGETING$155,764
P50 · FY2000 · HL